RA
Research concept · Proposed collaboration: dBme Research Group • Proposed pilot: Asperia Healthcare Limited
RAPID AMR WORKFLOW
Earlier answers. Better decisions.
Fast PCR screening. Targeted sequencing. A clearer path to review.
SCREENING TARGET2 hours
vs. 48–72h conventional AST
ESTIMATED CASE FEE৳1,200
No sequencing add-on
CURRENT ROUTEFast track
Screening-first approach
ACTIVE SPECIMEN
GAMR-BD-001 Fast-track MBL
Klebsiella pneumoniae (ST11) · 68M · endotracheal aspirate
LoadingMeropenem · empirical therapy
qPCR / Stage 2
● Local-first demo02 / MULTIPLEX SCREENING
Amplification, made visible
40 thermal cycles · synthetic logistic fluorescence · Ct is an input, not a fitted threshold crossing
● 16S rRNA● blaNDM● blaCTX-M● rmtB
Positive <35 · Borderline 35–38 · Negative >38. Adjusting the display threshold does not change the entered Ct.
RUN QUALITY
96-well plate
Internal control passed • synthetic melt peak 84.2°C
Synthetic melt-curve Tm table
| Target | Tm (°C) |
|---|---|
| 16S rRNA | 80.0 |
| blaNDM | 80.7 |
| blaCTX-M | 81.4 |
| rmtB | 82.1 |
Illustrative peaks; assay-specific validation pending.
10 multiplex target groups
- 16S rRNA + species
- blaNDM-1/5
- blaOXA-48/181/232
- blaKPC-2
- blaCTX-M-15/9
- blaSHV / blaTEM
- qnrB/qnrS + aac(6′)-Ib-cr
- rmtB/armA/aadB
- sul1/dfrA
- mcr-1
Target calls LIVE DEMO CONTROLS
POSITIVE
POSITIVE
NEGATIVE
NEGATIVE
POSITIVE
NEGATIVE
NEGATIVE
NEGATIVE
NEGATIVE
NEGATIVE
POSITIVE
NEGATIVE
NEGATIVE
NEGATIVE
NEGATIVE
NEGATIVE
⚡ Instant Demo Scenario Controller
Synthetic cases • gene and mutation controls are available in qPCR and Sanger.